Our new website will provide dialysis patients affected by the GranuFlo and NaturaLyte recall with important information regarding the risks associated with these products, and the legal options available to the victims of GranuFlo heart attacks.
New York, NY (PRWEB) March 20, 2013
Bernstein Liebhard LLP has launched a new GranuFlo lawsuit website to provide dialysis patients with important information regarding the GranuFlo and NaturaLyte recall announced by Fresenius Medical Care last year. GranuFlo and NaturaLyte are acid concentrates used during dialysis to remove toxins from the blood. In March 2012, Fresenius issued an “Urgent Product Notification” to its customer clinics warning of possible heart risks associated with the products. According to the notice, GranuFlo and NaturaLyte have the potential to cause a rapid and unsafe elevation of bicarbonate, which creates a substantially increased risk of cardiopulmonary arrest and death. The U.S. Food & Drug Administration (FDA) would later deem Fresenius’ notification a Class I GranuFlo recall, its most urgent type of recall.*
“Our new website will provide dialysis patients affected by the GranuFlo and NaturaLyte recall with important information regarding the risks associated with these products, and the legal options available to the victims of GranuFlo heart attacks and other serious side effects,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free GranuFlo lawsuit evaluations to dialysis patients who suffered cardiac arrest, heart attacks, stroke, sudden cardiac death or other side effects allegedly related to the administration of GranuFlo and NaturaLyte during dialysis.
GranuFlo and NaturaLyte Recall
According to a report published by The New York Times last June, the GranuFlo recall was announced months after Fresenius Medical Care issued a memo to dialysis clinics within its own network which warned that GranuFlo and NaturaLyte had been associated with serious heart side effects, and advised physicians to adjust dosage of the drugs in order to avoid this risk. The document, which was dated November 2011, reported that 941 patients had suffered cardiac arrest inside Fresenius clinics in 2010. According to the memo, the company’s own medical staff had determined that patients with high levels of bicarbonate in their blood had about six times the risk of cardiac arrest as those with lower levels. The FDA has since launched an investigation to determine if Fresenius Medical Care’s failure to issue an earlier warning to its customer clinics regarding the significant dangers associated with GranuFlo and Naturalyte may have violated the law.**
According to court records, dozens of GranuFlo lawsuits have already been filed by plaintiffs who allegedly suffered GranuFlo heart attacks and other catastrophic heart side effects following the administration of these dialysis drugs. Among other things, plaintiffs allege Fresenius marketed, distributed and sold GranuFlo and Naturalyte without adequate warnings and instructions concerning their risks. On March 21st, the U.S. Judicial Panel on Multidistrict Litigation (JPML) will hear oral arguments on the establishment of a multidistrict litigation in U.S. District Court, District of Massachusetts, for all federal product liability claims filed in the wake of the GranuFlo and NaturaLyte recall. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428 (JPML))
Dialysis patients who suffered heart attacks, sudden cardiac death, and other catastrophic heart side effects within 48 hours of a dialysis treatment with GranuFlo or NaturaLyte may be entitled to file a GranuFlo lawsuit to obtain compensation for medical expenses, lost wages, pain and suffering, and more. A wealth of information regarding GranuFlo heart attacks and other side effects is available at Bernstein Liebhard LLP’s website. For additional information about the GranuFlo and NaturaLyte recall, contact a lawyer at Bernstein Liebhard LLP today by calling (877) 779-1414.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP